There's no clear evidence yet that these drugs are directly causing pancreas damage
The effect depends on continued exposure there is no period after stopping during which the benefit persists on its own
The Cureus review found a similar pattern for oral semaglutide in the OASIS trials: high overall rates of adverse events in both active and placebo arms, dominated by gastrointestinal symptoms such as nausea, constipation, diarrhoea and vomiting, mostly mild to moderate, concentrated during dose titration, and rarely leading to permanent discontinuation, with very low rates of hypoglycaemia.
No GLP-1 patch is FDA approved: most are sold as wellness or supplement products that are never reviewed for dose or effectiveness before they reach the shelf
There are three pathways to produce propionate, including the acrylate, succinate, and the propanediol pathways